Literature DB >> 6975321

Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies.

J R Ortaldo, S O Sharrow, T Timonen, R B Herberman.   

Abstract

We examined highly purified populations of NK cells, T cells, monocytes, and PMN with a variety of monoclonal reagents presumed specific for T cells and monocytes. The enriched NK cells showed a pattern of reactivity that was distinct from that of the other 3 populations, sharing antigens with T cells but also sharing antigens with monocytes and/or PMN. A portion of the enriched NK cells expressed OKT8, OKT10, and Lyt-3 antigens that were reported previously as T cell-associated antigens, but no reactivity was seen with other T cell-associated antigens (OKT3, OKT4, OKT6, and OKT11). In addition a portion of the enriched NK cells were positive for OKM1, asialo-GM1, and Ia antigens, which are undetectable on typical T cells but are present on PMN and/or monocytes. By depletion of antigen-positive cells on antibody monolayers, it was found that the activity of the enriched NK population was associated mainly with cells reactive with OKT10, OKM1, and Lyt-3. Although considerable evidence exists to support the T lineage of NK cells, the sharing of some antigens by NK cells and monocytes has suggested a possible relationship of NK cells to cells of the monocyte lineage. A possibility certainly exists that NK cells are not in either T cell or monocyte lineages and may represent a separate lineage of lymphoid cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975321

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  98 in total

1.  Suppression of in vitro immunoglobulin synthesis by CD16(Leu11a)+ CD56 (NKH1,Leu19)+non-T lineage NK cells; lack of suppression of cells from immunodeficient patients.

Authors:  T Morio; S Nonoyama; J Yata
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Functional surface structures on human natural killer cells.

Authors:  R E Schmidt; T Hercend; S F Schlossman; J Ritz
Journal:  Klin Wochenschr       Date:  1985-12-02

3.  Purification and characterization of cytolytic and noncytolytic human natural killer cell subsets.

Authors:  L T Lebow; B Bonavida
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

4.  Circulating CD4+CD8+ cells in myasthenia gravis: supplementary immunological parameter for long-term prognosis.

Authors:  M Matsui; H Fukuyama; I Akiguchi; M Kameyama
Journal:  J Neurol       Date:  1989-09       Impact factor: 4.849

5.  Characterization with monoclonal antibodies of human lymphocytes active in natural killing and antibody-dependent cell-mediated cytotoxicity of dengue virus-infected cells.

Authors:  I Kurane; D Hebblewaite; F A Ennis
Journal:  Immunology       Date:  1986-07       Impact factor: 7.397

6.  Suppressive role of NK cells in pokeweed mitogen-induced immunoglobulin synthesis: effect of depletion/enrichment of Leu 11b+ cells.

Authors:  P D Mason; A P Weetman; J G Sissons; L K Borysiewicz
Journal:  Immunology       Date:  1988-09       Impact factor: 7.397

7.  Large granular lymphocytosis associated with rheumatoid arthritis.

Authors:  A Samanta; I Grant; F E Nichol; J H Pringle; J K Wood; A C Campbell
Journal:  Ann Rheum Dis       Date:  1988-10       Impact factor: 19.103

8.  Expression of T-cell associated antigens by porcine natural killer cells.

Authors:  M D Pescovitz; M A Lowman; D H Sachs
Journal:  Immunology       Date:  1988-10       Impact factor: 7.397

9.  The fine structure of HNK-1 (Leu7) positive cells. A study using an immunoperoxidase technique.

Authors:  G C Manara; G de Panfilis; C Ferrari; A Bonati; R Scandroglio
Journal:  Histochemistry       Date:  1984

10.  Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.

Authors:  H Hata; H Matsuzaki; F Matsuno; T Sonoki; S Takemoto; N Kuribayashi; A Nagasaki; K Takatsuki
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.